Clinical Trial Update: Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating EBV-specific cytotoxic T lymphocytes (GRALE) for EBV-positive lymphomas, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Lymphoproliferative Disorder
• Non-hodgkin Lymphoma

Drugs mentioned

• EBV-specific cytotoxic T lymphocytes (GRALE) (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hodgkin's Disease, Non-Hodgkin's Lymphoma | Phase 1 | Status: RECRUITING